Stemline Therapeutics Stock Company Profile

Description

Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States. It develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which is in Phase II clinical trial for advanced hematologic cancers; SL-701, an immunotherapy to attack tumors that is in Phase II clinical trial; and SL-801, a novel oral small molecule reversible inhibitor of nuclear transport, which is in Phase I clinical trial for the treatment of solid and hematologic cancers. The company also develops SL-501, a next generation IL-3R-targeted therapy and is in preclinical development. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.